Sanofi drops sharply on poor quarter
This article was originally published in Scrip
Executive Summary
Sanofi's earnings fell 24% in a "frustrating" second quarter, according CEO Christopher Viehbacher, resulting in the French pharma cutting its 2013 forecast guidance. Sanofi was hit by the residual impact of the patent cliff, an inventory problem in Brazil, and currency fluctuations.